类风湿关节炎患者第三次新冠疫苗接种后的血清转化受利妥昔单抗剂量影响但抗体持久性不受影响
在这项单中心观察性研究中,接受(超)低剂量利妥昔单抗治疗的类风湿关节炎患者中,第三次新冠疫苗接种后血清转化为19/98(19%),200mg组为5/13(38%),高于500mg组7/37(19%)和1000mg组7/48(15%);较低剂量与较晚接种时机呈非显著趋势;既往阳性体液应答在两次测量间接受利妥昔单抗输注后仍持久存在(96%和89%)。
要点
- 第三次接种后总体血清转化率为19/98(19%),200mg组5/13(38%)高于500mg组7/37(19%)和1000mg组7/48(15%)。
- 200mg vs 1000mg的OR为3.66(95%CI 0.93,14.0),每推迟一个月输注的OR为1.16(95%CI 0.97,1.35),均未达统计学显著。
- 既往体液应答阳性者中96%(22/23)和89%(8/9)在两次测量间接受利妥昔单抗后仍持久存在。
核心结论
- 在尽可能低的利妥昔单抗剂量后尽可能晚地重复接种疫苗似乎是最佳接种策略。
- 新冠疫苗接种后一旦出现阳性体液应答,即使期间接受利妥昔单抗输注仍持久存在。
研究设计与样本
- 单中心观察性研究,来自COVAC队列,196例患者中98例纳入第三次疫苗分析、23例纳入持久性分析。
- 第三次疫苗分析纳入既往无应答者第三次接种后2-6周获得体液应答者,持久性分析纳入既往应答者第三次接种前获得随访体液应答者。
- 阳性与阴性应答基于检测试剂盒cut-off二分,采用单变量logistic回归分析最近一次利妥昔单抗剂量及与接种的时间间隔和应答的关联。
主要发现
- 第三次接种后应答为19/98(19%)。
- 200mg利妥昔单抗使用者应答5/13(38%),500mg使用者7/37(19%),1000mg使用者7/48(15%)。
- 200mg vs 1000mg的OR为3.66(95%CI 0.93, 14.0),每输注后一个月OR为1.16(95%CI 0.97, 1.35),均为非显著趋势。
- 体液应答在两次测量间接受利妥昔单抗的患者中持久存在比例为96%(22/23)和89%(8/9)。
关键数值与推荐
- 阳性与阴性应答的判定基于检测试剂盒cut-off。
- 第三次接种后应答率:200mg组5/13(38%)vs 500mg组7/37(19%)vs 1000mg组7/48(15%)。
- 200mg vs 1000mg的OR为3.66(95%CI 0.93, 14.0)。
- 每输注后一个月OR为1.16(95%CI 0.97, 1.35)。
临床怎么用
- 作者认为,在尽可能低的利妥昔单抗剂量后尽可能晚地重复接种疫苗似乎是最佳接种策略。
- 作者指出,新冠疫苗接种后一旦出现阳性体液应答,即使期间接受利妥昔单抗输注仍持久存在。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In patients with RA treated with (ultra-)low-dose rituximab (RTX), we investigated the association of dosing and timing of RTX on seroconversion after a third coronavirus disease 2019 (COVID-19) vaccination and the persistence of humoral response after a two-dose vaccination. MATERIAL AND METHODS: In this monocentre observational study, patients from the COVAC cohort were included in the third vaccine analysis if humoral response was obtained 2-6 weeks after a third vaccination in previous non-responders and in the persistence analysis if a follow-up humoral response was obtained before a third vaccination in previous responders. Dichotomization between positive and negative response was based on the assay cut-off. The association between the latest RTX dose before first vaccination, timing between the latest RTX dose and vaccination and response was analysed with univariable logistic regression. RESULTS: Of the 196 patients in the cohort, 98 were included in the third vaccine analysis and 23 in the persistence analysis. Third vaccination response was 19/98 (19%) and was higher for 200 mg RTX users [5/13 (38%)] than for 500 and 1000 mg users [7/37 (19%) and 7/48 (15%), respectively]. Non-significant trends were seen for higher response with lower dosing [200 vs 1000 mg: odds ratio (OR) 3.66 (95% CI 0.93, 14.0)] and later timing [per month since infusion: OR 1.16 (95% CI 0.97, 1.35)]. Humoral response persisted in 96% (22/23) and 89% (8/9) of patients who received RTX between the two measurements. CONCLUSIONS: Repeated vaccination as late as possible after the lowest RTX dose possible seems the best vaccination strategy. A once positive humoral response after COVID-19 vaccination persists irrespective of intercurrent RTX infusion. Study registration. Netherlands Trial Registry (https://www.trialregister.nl/), NL9342.
引用
- van der Togt CJT, Ten Cate DF, van den Bemt BJF, et al. Seroconversion after a third COVID-19 vaccine is affected by rituximab dose but persistence is not in patients with rheumatoid arthritis. Rheumatology (Oxford). 2023. PMID: 36000861. doi:10.1093/rheumatology/keac486
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。